{"id":15961,"date":"2020-07-28T11:20:28","date_gmt":"2020-07-28T06:20:28","guid":{"rendered":"https:\/\/www.vosa.tv\/?p=15961"},"modified":"2020-07-28T11:20:28","modified_gmt":"2020-07-28T06:20:28","slug":"us-begins-final-tests-of-coronavirus-vaccine-candidate","status":"publish","type":"post","link":"https:\/\/www.vosa.tv\/eng\/archives\/15961","title":{"rendered":"US begins final tests of coronavirus vaccine candidate"},"content":{"rendered":"

ANKARA<\/strong><\/p>\n

Phase-three trials began on Monday of a candidate vaccine against the novel coronavirus in the US, with an expected enrollment of 30,000 volunteers, the National Institutes of Health announced.<\/p>\n

The vaccine was co-developed by biotechnology company Moderna, Inc., based in Cambridge, Massachusetts, and the National Institute of Allergy and Infectious Diseases (NIAID).<\/p>\n

The trial will be conducted at 89 US clinical research sites with adult volunteers who do not have COVID-19, according to the statement.<\/p>\n

NIAID Director Anthony Fauci said results from earlier clinical testing indicated that the vaccine was “safe and immunogenic, supporting the initiation of a Phase 3 clinical trial.”<\/p>\n

“This scientifically rigorous, randomized, placebo-controlled trial is designed to determine if the vaccine can prevent COVID-19 and for how long such protection may last.”<\/p>\n

The vaccine efficacy trial is the first to be implemented under Operation Warp Speed, a governmental program that aims to begin delivering millions of doses of an effective virus vaccine by the end of 2020.<\/p>\n

The trial is designed to determine if the vaccine can prevent symptomatic COVID-19 after two doses and it aims to study whether the vaccine can prevent severe infection with or without disease symptoms, the NIH said.<\/p>\n

It also seeks to answer whether the vaccine can prevent death caused by the virus and if just one dose can prevent symptomatic COVID-19, among other objectives.<\/p>\n

Trial volunteers will receive two injections approximately 28 days apart and some participants will be assigned at random to a control group that will be administered placebo doses.<\/p>\n

“The launch of this Phase 3 trial in record time while maintaining the most stringent safety measures demonstrates American ingenuity at its best and what can be done when stakeholders come together with unassailable objectivity toward a common goal,” NIH Director Francis Collins said.<\/p>\n

Investigators will use public health data and incidence trajectory modeling to identify sustained high-incidence areas and emerging hot zones, so sites near these locations can be prioritized for enrollment.<\/p>\n

The US government also backs the vaccine research of the Maryland-based Novavax biotechnology firm and Pfizer pharmaceutical corporation in New York City.<\/p>\n

The US is the worst-hit country by the pandemic with more than 4.2 million cases and nearly 147,000 deaths, according to a running tally of Johns Hopkins University. In all, nearly 1.3 million recoveries have been recorded.<\/p>\n

Many parts of the country have recently suffered new surges in virus cases.<\/p>\n","protected":false},"excerpt":{"rendered":"

ANKARA Phase-three trials began on Monday of a candidate vaccine against the novel coronavirus in the US, with an expected enrollment of 30,000 volunteers, the National Institutes of Health announced. The vaccine was co-developed by biotechnology company Moderna, Inc., based in Cambridge, Massachusetts, and the National Institute of Allergy and Infectious Diseases (NIAID). The trial […]<\/p>\n","protected":false},"author":5,"featured_media":15277,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,1378],"tags":[],"class_list":["post-15961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-us"],"_links":{"self":[{"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/posts\/15961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/comments?post=15961"}],"version-history":[{"count":1,"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/posts\/15961\/revisions"}],"predecessor-version":[{"id":15962,"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/posts\/15961\/revisions\/15962"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/media\/15277"}],"wp:attachment":[{"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/media?parent=15961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/categories?post=15961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vosa.tv\/eng\/wp-json\/wp\/v2\/tags?post=15961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}